BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
15 januari, 2025
15 januari, 2025
BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.
Read the article at biostock.se:
Elicera’s candidate ELC-100 granted Orphan Drug Designation
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
15 januari, 2025
BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.
Read the article at biostock.se:
Elicera’s candidate ELC-100 granted Orphan Drug Designation
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Rapporter
AstraZeneca
Aktieanalys
Rapporter
AstraZeneca
Aktieanalys
1 DAG %
Senast
OMX Stockholm 30
1,32%
(14:01)
OMX Stockholm 30
1 DAG %
Senast
3 317,77